Share on StockTwits

Equities research analysts at Needham & Company LLC reduced their target price on shares of Galena Biopharma (NASDAQ:GALE) from $9.00 to $7.00 in a research note issued to investors on Tuesday. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s target price points to a potential upside of 128.76% from the company’s current price.

Separately, analysts at Roth Capital raised their price target on shares of Galena Biopharma to $8.00 in a research note on Tuesday, July 22nd. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Galena Biopharma has a consensus rating of “Buy” and a consensus target price of $6.67.

Galena Biopharma (NASDAQ:GALE) opened at 2.76 on Tuesday. Galena Biopharma has a 52-week low of $1.66 and a 52-week high of $7.77. The stock’s 50-day moving average is $2.93 and its 200-day moving average is $3.01. The company’s market cap is $325.7 million.

Galena Biopharma (NASDAQ:GALE) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.08. The company had revenue of $2.30 million for the quarter, compared to the consensus estimate of $2.99 million. On average, analysts predict that Galena Biopharma will post $-0.30 earnings per share for the current fiscal year.

Galena Biopharma, Inc (NASDAQ:GALE), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics.

Receive News & Ratings for Galena Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.